Post hoc analysis of a phase 3b trial in children with persistent or chronic ITP: platelet response by day 22 was 75.9% with avatrombopag vs 0% with placebo; 92.6% (50/54) reached ≥30×10⁹/L. Results were similar across subgroups; 61.1% had dose holds for high counts.
Secondary analysisn = 54
Grace et al. Avatrombopag for persistent and chronic immune thrombocytopenia in children: A post hoc analysis of clinical characteristics of response from a phase 3b clinical trial